Laizure SC, Herring V, Hu Z, Witbrodt K, Parker RB. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 2013;33:210–22.CrossrefPubMedWeb of ScienceGoogle Scholar
Rasmussen HB, Bjerre D, Linnet K, Jürgens G, Dalhoff K, Stefansson H, et al. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. Pharmacogenomics 2015;16:649–65.PubMedWeb of ScienceCrossrefGoogle Scholar
Fukami T, Nakajima M, Maruichi T, Takahashi S, Takamiya M, Aoki Y, et al. Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics 2008;18:911–20.Web of ScienceCrossrefPubMedGoogle Scholar
Yoshimura M, Kimura T, Ishii M, Ishii K, Matsuura T, Geshi E, et al. Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites. Biochem Biophys Res Commun 2008;369:939–42.CrossrefPubMedGoogle Scholar
Nelveg-Kristensen KE, Madsen MB, Torp-Pedersen C, Køber L, Egfjord M, Hansen T, et al. Prognostic impact of carboxylesterase 1 gene variants in patients with congestive heart failure treated with angiotensin-converting enzyme inhibitors. Pharmacogenet Genomics 2016;26:169–77.CrossrefWeb of ScienceGoogle Scholar
Sai K, Saito Y, Tatewaki N, Hosokawa M, Kaniwa N, Nishimaki-Mogami T, et al. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. Br J Clin Pharmacol 2010;70:222–33.CrossrefPubMedWeb of ScienceGoogle Scholar
Wang X, Wang G, Shi J, Aa J, Comas R, Liang Y, et al. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. Pharmacogenomics J 2016;16:220–30.Web of ScienceCrossrefPubMedGoogle Scholar
Geshi E, Kimura T, Yoshimura M, Suzuki H, Koba S, Sakai T, et al. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res Off J Jpn Soc Hypertens 2005;28:719–25.CrossrefGoogle Scholar
Zhu H-J, Langaee TY, Gong Y, Wang X, Pepine CJ, Cooper-DeHoff RM, et al. CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. Eur J Clin Pharmacol 2016;72:681–7.CrossrefWeb of SciencePubMedGoogle Scholar
Shi J, Wang X, Nguyen J-H, Bleske BE, Liang Y, Liu L, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol 2016;119:76–84.CrossrefPubMedWeb of ScienceGoogle Scholar
Zhu H-J, Patrick KS, Yuan H-J, Wang J-S, Donovan JL, DeVane CL, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 2008;82:1241–8.Web of ScienceCrossrefPubMedGoogle Scholar
About the article
Published Online: 2017-08-14
Published in Print: 2017-09-26
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: The Danish Council for Strategic Research, Programme Commission on Individuals, Disease and Society, grant 10-092792/DSF.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.